Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$5.00 USD
+0.14 (2.88%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $5.00 0.00 (0.00%) 5:40 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 161 - 180 ( 406 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Top and Bottom-Line Beat; All Eyes on Libervant; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
FDA Accepts Libervant Resubmission for Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant NDA Resubmission Accepted, PDUFA Set for December 23, 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant New Drug Application Resubmitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant NDA Resubmitted On Schedule, PDUFA Expected in Late 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L